title: Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy.
abstract: Cisplatin/pemetrexed chemotherapy has been established as a standard treatment in lung adenocarcinoma. However, the response to the cisplatin/pemetrexed combination varies considerably among patients due to individual variations. Thus, novel biomarkers are required to aid the prediction of the response to the cisplatin/pemetrexed combination. We hypothesized that leptin expression may be a determinant for prognosis in lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Serum from consenting patients with lung adenocarcinoma were obtained for the measurement of leptin and associated tumor biomarkers. Leptin expression was measured by radioimmunoassay. Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA15-3, CA125, CA72-4, cytokeratin 19 fragment (CYFRA21-1) and neuron-specific enolase (NSE) expression were determined by electrochemiluminescence immunoassays. Serum squamous cell carcinoma antigen levels were measured using a microparticle enzyme immunoassay. The associations between serum leptin and tumor biomarker expression were evaluated by Spearman's correlation analysis. Serum CEA, CA19-9, CA15-3, CA125, CA72-4, CYFRA21-1 and NSE levels showed no obvious difference among patients. However, a trend towards an improved prognosis was observed in patients with lower serum leptin at diagnosis and an increase during cisplatin/pemetrexed chemotherapy. The results indicated that the serum leptin level has prognostic indications in patients with advanced lung adenocarcinoma during cisplatin/pemetrexed chemotherapy, which indicates that it may be a useful marker for the prognosis of cancer patients undergoing chemotherapy treatment.
authors.affiliation: School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Mou
authors.affiliation: Research Laboratory of Biochemistry, Basic Medical Institute, Beijing 100853, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Xue
authors.affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Hongli
authors.initials: H
authors.lastname: Tong
authors.affiliation: Oncology Department, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Shengjie
authors.initials: S
authors.lastname: Sun
authors.affiliation: School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Zhuhong
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Qiyu
authors.initials: Q
authors.lastname: Sun
authors.affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Dong
authors.affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Xinyu
authors.initials: X
authors.lastname: Wen
authors.affiliation: Research Laboratory of Biochemistry, Basic Medical Institute, Beijing 100853, P.R. China.
authors.forename: Guangtao
authors.initials: G
authors.lastname: Yan
authors.affiliation: School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China.
authors.forename: Yaping
authors.initials: Y
authors.lastname: Tian
keywords: cisplatin/pemetrexed; leptin; lung adenocarcinoma; prognosis